The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

Category: Editor’s Choice

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Editor's Choice

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

APR 25, 2023
Researchers create virus-resistant, safely restrained E. coli
Editor's Choice

Researchers create virus-resistant, safely restrained E. coli

APR 10, 2023
“Probiotics” Green-lit for market-usage by French Authorities
Biotics and Supplements

“Probiotics” Green-lit for market-usage by French Authorities

JAN 25, 2023
Microbiome Drug Development: 2022 in Review
Editor's Choice

Microbiome Drug Development: 2022 in Review

DEC 30, 2022
Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals
Editor's Choice

Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals

DEC 22, 2022
FDA Approves First Fecal Microbiota Product
Editor's Choice

FDA Approves First Fecal Microbiota Product

DEC 1, 2022
Proge Farm claims Europe’s first regulatory approval for a microbiome-based therapeutic
Editor's Choice

Proge Farm claims Europe’s first regulatory approval for a microbiome-based therapeutic

NOV 29, 2022
Seres Therapeutics Announces FDA acceptance of Biologics License Application For Ser-109
Editor's Choice

Seres Therapeutics Announces FDA acceptance of Biologics License Application For Ser-109

OCT 28, 2022
A microbiome therapeutic is closer than ever to market authorization in the US. What does it mean for the industry?
Editor's Choice

A microbiome therapeutic is closer than ever to market authorization in the US. What does it mean for the industry?

SEP 28, 2022
Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
Editor's Choice

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

SEP 23, 2022
Stanford researchers construct most complex, complete synthetic microbiome
Editor's Choice

Stanford researchers construct most complex, complete synthetic microbiome

SEP 9, 2022